Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články
PubMed
27774694
DOI
10.1111/1346-8138.13661
Knihovny.cz E-zdroje
- Klíčová slova
- adalimumab, atherosclerosis, biomarkers, cardiovascular, psoriasis,
- MeSH
- adalimumab aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- beta-2-glykoprotein I krev MeSH
- biologické markery krev MeSH
- C-reaktivní protein analýza MeSH
- cévní buněčněadhezivní molekula-1 krev MeSH
- dermatologické látky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- dospělí MeSH
- E-selektin krev MeSH
- interleukin 22 MeSH
- interleukiny krev MeSH
- kardiovaskulární nemoci krev komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoproteiny LDL krev MeSH
- pilotní projekty MeSH
- psoriáza krev komplikace farmakoterapie MeSH
- rizikové faktory MeSH
- TNF-alfa antagonisté a inhibitory MeSH
- zdraví dobrovolníci pro lékařské studie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- adalimumab MeSH
- beta-2-glykoprotein I MeSH
- biologické markery MeSH
- C-reaktivní protein MeSH
- cévní buněčněadhezivní molekula-1 MeSH
- dermatologické látky MeSH
- E-selektin MeSH
- interleukiny MeSH
- lipoproteiny LDL MeSH
- oxidized low density lipoprotein MeSH Prohlížeč
- SELE protein, human MeSH Prohlížeč
- TNF-alfa MeSH
Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
Citace poskytuje Crossref.org
